Atopic Dermatitis Treated With Dupilumab and JAK Inhibitors in Costa Rica

This registry specifically focuses on patients with moderate-to-severe atopic dermatitis receiving systemic immunosuppressive or biologic therapies in real-world clinical practice in Costa Rica. Unlike clinical trials or other dermatologic registries, this study captures routine-care treatment patterns, including conventional systemic agents and newer targeted biologics used according to physician judgment without protocol-mandated interventions. The registry uniquely characterizes disease severity, treatment response, and quality-of-life outcomes in the Costa Rican population across multiple centers, enabling evaluation of effectiveness, safety, and persistence of advanced therapies in everyday practice rather than controlled research settings.

This registry specifically focuses on patients with moderate-to-severe atopic dermatitis receiving systemic immunosuppressive or biologic therapies in real-world clinical practice in Costa Rica. Unlike clinical trials or other dermatologic registries, this study captures routine-care treatment patterns, including conventional systemic agents and newer targeted biologics used according to physician judgment without protocol-mandated interventions. The registry uniquely characterizes disease severity, treatment response, and quality-of-life outcomes in the Costa Rican population across multiple centers, enabling evaluation of effectiveness, safety, and persistence of advanced therapies in everyday practice rather than controlled research settings.

This registry specifically focuses on patients with moderate-to-severe atopic dermatitis receiving systemic immunosuppressive or biologic therapies in real-world clinical practice in Costa Rica. Unlike clinical trials or other dermatologic registries, this study captures routine-care treatment patterns, including conventional systemic agents and newer targeted biologics used according to physician judgment without protocol-mandated interventions. The registry uniquely characterizes disease severity, treatment response, and quality-of-life outcomes in the Costa Rican population across multiple centers, enabling evaluation of effectiveness, safety, and persistence of advanced therapies in everyday practice rather than controlled research settings.

This registry specifically focuses on patients with moderate-to-severe atopic dermatitis receiving systemic immunosuppressive or biologic therapies in real-world clinical practice in Costa Rica. Unlike clinical trials or other dermatologic registries, this study captures routine-care treatment patterns, including conventional systemic agents and newer targeted biologics used according to physician judgment without protocol-mandated interventions. The registry uniquely characterizes disease severity, treatment response, and quality-of-life outcomes in the Costa Rican population across multiple centers, enabling evaluation of effectiveness, safety, and persistence of advanced therapies in everyday practice rather than controlled research settings.